---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-034843"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:00:21.673556+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CVRx BeAT-HF trial: safety endpoint met, symptom improvement shown; primary endpoint not significant

## Summary
- Safety: MANCE event-free rate of 97% (p<0.001).
- Symptom improvement: 6-min walk +44m at 12mo, QoL +10 pts at 24mo (p<0.001).
- Primary endpoint (CV death, LVAD, transplant, HF hospitalizations) not significant (RR 0.94, p=0.82).
- All-cause mortality showed 34% relative reduction favoring BAT (HR 0.66, p=0.054).
- CEO plans FDA submission in coming months for expanded labeling.

## SEC filing metadata
- accession: 0001104659-23-034843
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465923034843/0001104659-23-034843-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465923034843/tm2310097d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-034843
- JSON: https://secwatch.observer/filing/0001104659-23-034843.json
- Plain text: https://secwatch.observer/filing/0001104659-23-034843.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.